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Nicotinic acid adenine dinucleotide phosphate represents a newly identiﬁed second messenger in T cells involved in antigen
receptor-mediated calcium signalling. Its function in vivo is, however, unknown due to the lack of biocompatible inhibitors.
Using a recently developed inhibitor, we explored the role of nicotinic acid adenine dinucleotide phosphate in autoreactive
effector T cells during experimental autoimmune encephalomyelitis, the animal model for multiple sclerosis. We provide in vitro
and in vivo evidence that calcium signalling controlled by nicotinic acid adenine dinucleotide phosphate is relevant for the
pathogenic potential of autoimmune effector T cells. Live two photon imaging and molecular analyses revealed that nicotinic
acid adenine dinucleotide phosphate signalling regulates T cell motility and re-activation upon arrival in the nervous tissues.
Treatment with the nicotinic acid adenine dinucleotide phosphate inhibitor signiﬁcantly reduced both the number of stable
arrests of effector T cells and their invasive capacity. The levels of pro-inﬂammatory cytokines interferon-gamma and inter-
leukin-17 were strongly diminished. Consecutively, the clinical symptoms of experimental autoimmune encephalomyelitis were
ameliorated. In vitro, antigen-triggered T cell proliferation and cytokine production were evenly suppressed. These inhibitory
effects were reversible: after wash-out of the nicotinic acid adenine dinucleotide phosphate antagonist, the effector T cells fully
regained their functions. The nicotinic acid derivative BZ194 induced this transient state of non-responsiveness speciﬁcally in
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adenine dinucleotide phosphate receptor, type 1 ryanodine receptor, were not targeted. T cell priming and recall responses
in vivo were not reduced. These data indicate that the nicotinic acid adenine dinucleotide phosphate/calcium signalling pathway
is essential for the recruitment and the activation of autoaggressive effector T cells within their target organ. Interference with
this signalling pathway suppresses the formation of autoimmune inﬂammatory lesions and thus might qualify as a novel
strategy for the treatment of T cell mediated autoimmune diseases.
Keywords: experimental autoimmune encephalomyelitis; multiple sclerosis; T cell signalling; nicotinic acid adenine dinucleotide
phosphate; intravital imaging
Abbreviations: DMSO=dimethyl sulphoxide; GFP=green ﬂuorescent protein; (
3H)dT=(
3H)-20-deoxy-thymidine; IFN- =inter-
feron-gamma; IP3= D-myo-inositol 1,4,5-trisphosphate; MBP=myelin basic protein; NAADP=nicotinic acid adenine dinucleotide
phosphate; OVA=ovalbumin; EAE=experimental autoimmune encephalomyelitis.
Introduction
Elevation of the free cytosolic and nuclear Ca
2+ concentration is an
essential event during T cell activation and is controlled by a com-
plex network of different molecules. The major source of Ca
2+ is
the extracellular space. Ca
2+ entry from this extracellular source is
guided by the recently discovered Ca
2+ channels Orai1/Ca
2+
release-activated Ca
2+ channel membrane protein 1 (CRACM1)
(Feske et al., 2006; Peinelt et al., 2006; Vig et al., 2006;
Yeromin et al., 2006). The opening of these channels, however,
requires continuous Ca
2+ release from intracellular pools. The best
known Ca
2+ mobilizing second messenger is D-myo-inositol 1,4,5-
trisphosphate (IP3) (Streb et al., 1983), but two additional mole-
cules, cyclic ADP-ribose (Guse et al., 1999) and nicotinic acid
adenine dinucleotide phosphate (NAADP) (Berg et al., 2000),
were found to release Ca
2+ from the intracellular pool of T cells.
Recent work in Jurkat lymphoma cells indicates that a timely coor-
dinated release and interplay of these three messengers is required
in shaping the Ca
2+ signal after T cell receptor-triggered antigen
stimulation (Guse et al., 1999; Gasser et al., 2006).
Due to a lack of biocompatible and speciﬁc inhibitors, the func-
tional impact of each distinct Ca
2+-mobilizing second messenger
following antigen-driven activation is less well understood.
Recently, we developed an antagonist, BZ194, which interferes
selectively with NAADP-mediated Ca
2+ release via the type 1 rya-
nodine receptor in T cells. Initial in vitro analyses of the functional
consequences of NAADP antagonism revealed that BZ194 efﬁ-
ciently suppressed T cellular interleukin-2 production and prolifera-
tion (Dammermann et al., 2009).
Since effector T cells reactive against self-antigens are thought
to cause organ-speciﬁc autoimmune diseases (Steinman et al.,
1995), we investigated here the therapeutic potential of BZ194
in experimental autoimmune encephalomyelitis (EAE), the classic
T cell mediated animal model for multiple sclerosis (Wekerle et al.,
1994). We genetically labelled the effector T cell population to
track the disease-inducing cell populations upon NAADP inhibition
in vivo (Flu ¨gel et al., 1999). Our data demonstrate that NAADP-
driven reactivation of autoaggressive effector T cells within their
target organs plays an essential role in the induction of autoim-
mune diseases of the nervous system.
Materials and methods
Materials
Fura-2/AM was purchased from Calbiochem. NAADP and dimethyl
sulphoxide (DMSO) were supplied by Sigma. BZ194 was synthesized
as described (Dammermann et al., 2009).
Animals
Lewis and DA rats were obtained from the animal breeding facilities of
the Max Planck Institute for Biochemistry (Martinsried, Germany) and
kept under standardized conditions. All experiments were conducted
according to Bavarian state regulations for animal experimentation and
approved by the responsible authorities.
Generation and culture of
effector T cells
Antigen-speciﬁc effector T cell clones were obtained from lymph node
preparations of immunized Lewis rats. Stimulation, expansion and cul-
ture of speciﬁc rat T cells were conducted as described (Flu ¨gel et al.,
1999). Details concerning generation of myelin basic protein (MBP)-
and ovalbumin (OVA)-speciﬁc CD4
+ T cells (TMBP and TOVA cells)
retrovirally engineered to express the marker gene EGFP are provided
in the Supplementary Methods section.
Proliferation assays of T cells
Antigen-speciﬁc rat T cells (TMBP and TOVA cells) were co-cultured for
48h in 96-well plates (in Dulbecco’s modiﬁed Eagle’s medium 1% rat
serum) with irradiated professional thymic antigen presenting cells as
previously described (Flu ¨gel et al., 1999), in presence of speciﬁc or
control antigen (10mg/ml MBP or OVA) and BZ194 in DMSO, or
DMSO alone. Ampliﬁcation of TMBP-GFP cells was measured either by
cytoﬂuorometry or by (
3H)-20-deoxy-thymidine [(
3H)dT; 2Ci/mmol;
Amersham] incorporation. Further details are included in the
Supplementary Methods section. To rule out that BZ194 treatment
interferes with the T cell proliferation machinery, TMBP cell blasts
2 days following stimulation with MBP-pulsed professional antigen
presenting cells were incubated with increasing amounts of BZ194
and their numbers determined 24, 48 and 96h later by cytoﬂuorome-
try. After removal of BZ194 the T cells were then re-stimulated with
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3H)dT incorporation was used to
evaluate proliferation after 2 days culture.
To test antigen reactivity of BZ194-treated T cells, the cells were
ﬁrst stimulated with MBP-pulsed antigen presenting cells in the pre-
sence of increasing amounts of BZ194 for 48h, or in the presence of
vehicle alone (DMSO, vehicle). Thereafter, the cells were rechallenged
with MBP-pulsed antigen presenting cells and their proliferation rate
was evaluated 2 days later by (
3H)dT incorporation. For stimulation of
effector and naı ¨ve T cells by anti-CD3/anti-CD28 antibodies (Serotec),
96-well plates were coated for 2h at room temperature with 5mg/ml
of each antibody in phosphate buffered saline. Rat TMBP and TOVA
effector cells or OX 22
high (CD45-RC
+) naı ¨ve T cells were plated at
the ﬁnal concentration of 10
5 cells/well. After Day 2 of culturing,
(
3H)dT incorporation was measured. Naive CD45-RC
+ T cells (Powrie
and Mason, 1988; Ramirez and Mason, 2000) were isolated from
lymph nodes of untreated animals using ﬂuorescence activated cell
sorting (FACS Vantage, Becton Dickinson).
Memory T cells were prepared as described (Kawakami et al.,
2005b). More information is provided in the Supplementary
Methods section.
EAE and BZ194 application in vivo
For induction of transfer EAE, 5 10
6 MBP-reactive GFP
+ T cells were
injected i.v. into healthy recipient rats. Active EAE was induced by
intra-cutaneous injection of 100mg MBP emulsiﬁed in complete
Freund’s adjuvant containing Mycobacterium tuberculosis (4mg/ml;
DIFCO). Animals were monitored daily by measuring weight and
examining disease scores as follows: 0=no disease; 1=ﬂaccid tail;
2=gait disturbance; 3=complete hind limb paralysis; 4=tetraparesis;
5=death. The observation time was extended to more than 30 days
during active EAE and 21 days during adoptive transfer EAE.
For treatment, daily i.p. injections of BZ194 (500mM, 180mg/kg,
solubilized in DMSO/1% Lewis rat serum), DMSO (0.8ml/kg) or nico-
tinic acid (500mM, 61.5mg/kg, solubilized in DMSO/1% Lewis rat
serum) were performed. Application of BZ194 in concentrations of
up to 1mM for 7 days or 0.5mM for 14 days did not show any
overt toxic effect. Treatment with 180mg/kg BZ194 per day was
chosen since this dose resulted in serum levels of  300mM, as deter-
mined by a T cell proliferation bioassay (Supplementary Fig. 12;
Supplementary Methods section). This concentration was sufﬁcient
to suppress proliferation of TMBP effector cells (Fig. 3A and B, 5A).
Antigen presentation capacity of
BZ194-treated lymph node cells
Lymph node cells from BZ194- or DMSO-treated animals were har-
vested and irradiated (5000rad). Resting TMBP or TOVA cells were then
added to the cultures and proliferation in the presence of speciﬁc or
control antigen (10mg/ml MBP or OVA, respectively) was determined
by (
3H)dT incorporation 2 days later.
Mylein basic protein-reactive antibody
production after BZ194 treatment of
myelin basic protein immunized animals
Vinyl plates (96-well) (Corning-Costar) were coated with MBP
(10mg/ml) for 1h at 37 C in a buffer containing 0.025M Na2CO3
and 0.025M NaHCO3. Blood samples were taken 0, 7 and 14 days
after immunization. Detection of MBP-speciﬁc antibodies was
performed via enzyme-linked immunosorbent assay on different
serum dilutions (1:500, 1:1000 and 1:2000). More information is pro-
vided in the Supplementary Methods section.
Quantitative polymerase chain reaction
and enzyme-linked immunosorbent
assays
Detailed information is provided in the Supplementary Methods
section.
Cell isolation, cytoﬂuorometry,
ﬂuorescence-activated cell sorting
and immunohistochemistry
Single cell suspensions from organs were prepared as described pre-
viously (Flu ¨gel et al., 2001). Detailed information is provided in the
Supplementary Methods section.
Chemotaxis assays
Ex vivo isolated or in vitro cultured effector T cells were tested for
their ability to pass through a 5mm pore membrane following a che-
mokine gradient by using transwell plates (Corning-Costar). Detailed
information is provided in the Supplementary Methods section.
Lipopolysaccharide-induced central
nervous system inﬂammtion
Lipopolysaccharide (150ng) from Escherichia coli 0127:B8 (Sigma) in
a volume of 25ml or an equivalent volume of phosphate buffered
saline was intrathecally injected into the cisterna magna of anaesthe-
tized animals.
Live imaging
Preparation of acute spinal cord slices and live imaging were per-
formed as described (Kawakami et al., 2005b; Bartholoma ¨us et al.,
2009). Detailed information is provided in the Supplementary
Methods section.
Statistical analysis
For statistical evaluation a two-tailed t-test with homeostatic variance
was used in all assays except clinical evaluation of EAE, where the
Mann–Whitney U-ranking test was applied using the MedCalc soft-
ware (http://www.medcalc.be).
Results
NAADP antagonist BZ194 ameliorates
experimental autoimmune
encephalomyelitis
The role of NAADP signalling in T cell-mediated autoimmune dis-
eases was tested using BZ194 (Supplementary Fig. 1), a lipophilic
derivative of the nicotinic acid group of the molecule
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NAADP antagonist (12 days, 180mg/kg i.p.) without any appar-
ent adverse effect. The size and the cellularity of primary and
secondary lymph organs and the blood were not altered
(Supplementary Fig. 2A). The reactivity of the lymph node cells,
as tested in mixed lymphocyte reactions (Supplementary Fig. 2B)
and the antigen presenting capacity of ex vivo isolated antigen
presenting cells remained unaffected (Supplementary Fig. 2C).
The incidence and severity of clinical EAE induced by active
immunization with MBP was signiﬁcantly reduced by BZ194
(Fig. 1A; Table 1). This was accompanied by a decreased inﬂam-
mation of the spinal cord, the preferentially affected CNS location
in this EAE model (Supplementary Fig. 3A–C). Notably, BZ194
injection immediately before onset of the clinical disease, i.e. in
the ‘effector’ phase of EAE, was similarly effective as when ‘pre-
ventively’ applied, i.e. during the ‘priming’ phase of EAE, simulta-
neously with immunization (Fig. 1B, Table 1). Active EAE evolves
in two phases: during the initial disease-free phase, naı ¨ve T cells
carrying the appropriate antigen-receptor become activated within
the draining lymph nodes upon encounter of the applied brain
antigen presented by professional antigen presenting cells. In the
second phase, the ‘primed’ cells then migrate as effector T cells
into the CNS where they re-encounter endogenous brain antigen
presented by local antigen presenting cells. The ensuing re-activa-
tion and cytokine production of the autoaggressive effector T cells
initiate and drive CNS inﬂammation and paralytic disease
(Kawakami et al., 2004).
Obviously, BZ194 did not impair the stimulation of naı ¨ve T cells
during the primary immune responses after immunization: T cell
proliferation within draining lymph nodes, pro-inﬂammatory cyto-
kine production and MBP-speciﬁc antibody responses were not
changed (Fig. 1C–E).
NAADP antagonist BZ194 induces a
transient state of non-responsiveness
to antigen stimulation of (auto)antigen
experienced effector T cells
These observations led us to explore the effects of BZ194 on post-
activated effector T cells. To this end, we generated MBP-speciﬁc
CD4
+ T cell lines (Ben-Nun et al., 1981). The NAADP antagonist
signiﬁcantly reduced Ca
2+ signalling (Supplementary Fig. 4A), pro-
liferation (Fig. 2A) and the production of interleukin-2 upon anti-
gen receptor-triggered stimulation (Dammermann et al., 2009).
Additionally, the levels of the pro-inﬂammatory cytokines inter-
feron-gamma (IFN-) and interleukin-17 were signiﬁcantly
reduced (Supplementary Fig. 4B and C). The expression of inter-
leukin-4 remained barely detectable, the levels of interleukin-10,
TNF and the chemokine receptors C-X-C chemokine receptor
type 3 (CXCR3) and C-C chemokine receptor type 5 (CCR5)
were not signiﬁcantly changed. The early growth response genes
2 and 3 (egr2 and egr3) were strongly up-regulated
(Supplementary Fig. 4D).
Notably, the effect of BZ194 was reversible: after wash-out of
BZ194 the effector T cells regained responsivity to their antigen.
Re-challenge with antigen-pulsed antigen presenting cells after
wash-out of BZ194 completely restored proliferation and cytokine
production of the T cells (scheme in Fig. 2A and B; Supplementary
Fig. 4E). BZ194 was efﬁcient when applied before the T cells came
in contact with antigen-pulsed antigen presenting cells. This is
most likely due to the fact that NAADP-mediated Ca
2+ ﬂuxes
occur early during T cell activation (Gasser et al., 2006).
Accordingly, BZ194 did not impair T cell proliferation when it
was applied after this early stimulation phase, i.e. 48h after co-
cultivation with antigen presenting cells (scheme in Fig. 2C and D).
Even upon prolonged BZ194 exposure (up to 96h) after wash-out,
the effector T cells grew indistinguishably from untreated cells
when speciﬁcally stimulated with MBP (Fig. 2D). The suppressive
effects of BZ194 were not due to interference with the function of
antigen presenting cells, since T cell proliferation was efﬁciently
inhibited by BZ194 after stimulating the cells in the absence of
antigen presenting cells using anti-CD3 and anti-CD28 antibodies
(Fig. 3A and B). Furthermore, pretreatment of antigen presenting
cells with BZ194 for 2 and 16h did not change their capacity to
stimulate effector MBP- or OVA-speciﬁc T cells (Supplementary
Fig. 5).
Naı ¨ve and memory T cells are less
susceptible to NAADP antagonism
Remarkably, we observed a clear difference between the inhibitory
potency of BZ194 for antigen-experienced effector T cells and OX
22
high (CD45-RC
+) naı ¨ve T cells, i.e. T cells that had not been
confronted with antigen before (Powrie and Mason, 1988,
Ramirez and Mason, 2000). While the proliferation of cultured
(Fig. 3A) or ex vivo-isolated (Supplementary Fig. 6A) antigen-
experienced effector T cells was inhibited starting at a concentra-
tion of  50mM BZ194, naı ¨ve cells responded to the treatment
only at more than 10-fold higher concentrations (5750mM,
Fig. 3A). Reduced sensitivity to BZ194 was also detected in
long-lived memory T cells.
The proliferation of OVA-reactive memory TGFP cells that had
been instilled into neonatal animals and that had persisted for 6
months as classical resting memory T cells (Kawakami et al.,
2005b) was suppressed starting at 5500mM BZ194 (Fig. 3B).
Similar data were obtained with human naive and memory T
cell responses (Supplementary Fig. 6B). The differential susceptibil-
ity to BZ194 correlated with the expression of ryanodine receptor
1, which was recently identiﬁed as the putative receptor for
NAADP-triggered Ca
2+ signalling in T cells (Dammermann et al.,
2009). Ryanodine receptor 1 was signiﬁcantly up-regulated in
effector T cells as compared to naı ¨ve and memory T cells (Fig. 3C).
NAADP antagonism interferes with
re-activation of autoaggressive effector
T cells within their target organ
We next explored the effects of NAADP antagonist BZ194 on
autoaggressive effector T cells in vivo. For this purpose we
induced EAE by transfer of activated effector TMBP cells that
were retrovirally engineered to express green ﬂuorescent protein
(GFP) as genetic marker (effector TMBP-GFP cells) (Flu ¨gel et al.,
NAADP interference in T cell-mediated autoimmunity Brain 2010: 133; 1930–1943 | 1933Figure 1 NAADP-antagonist BZ194 ameliorates active EAE without preventing primary immune responses. (A and B) Treatment of active
EAE. Clinical course (left) and incidence rate (right; depicted as Kaplan–Meier curve) of active EAE after preventive (A; n=16 animals/
group) and effector phase (B; n=5 animals/group) treatment with BZ194 (black) or vehicle (DMSO, white). Grey bar: period of treatment:
Days 0–14 post injection (p.i.) (A), Days 8–14p.i. (B). Cumulative data of three (A) and two (B) independent experiments are shown
(means SD). P-values evaluated by Mann–Whitney rank statistical test: *P 0.05, **P 0.001, ***P 0.0001. (C–E) NAADP
Continued
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clinical signs, signiﬁcantly suppressed clinical disease and CNS
inﬂammation (Fig. 4A and B; Table 1; Supplementary Fig. 7).
Effector TMBP-GFP cells were reduced in their target organ in
BZ194- compared to DMSO-treated control animals, while their
numbers in spleen, lymph nodes and blood were increased
(Fig. 4C; Supplementary Fig. 7A). These changes were most
likely due to effects on the autoaggressive effector T cells:
TMBP-GFP cells within the CNS showed strongly diminished expres-
sion of pro-inﬂammatory cytokines (Fig. 4D).
Notably, this reduced invasion of the attacked organs cannot be
explained by the different expression of adhesion molecules and
chemokine receptors of BZ194-treated effector T cells
(Supplementary Fig. 8). Their capacity to follow chemotactic sti-
muli was not hindered by BZ194 treatment. C-X-C chemokine
ligand (CXCL)10- and CCL5-induced migration of cultured and
spleen-retrieved effector T cells was unchanged (Fig. 4E).
Furthermore, BZ194 did not inﬂuence the invasion of brain-
ignorant, OVA-reactive effector T cells into the inﬂammatory
CNS lesions induced by intrathecal lipopolysaccharide-injection
(Fig. 4F).
To conﬁrm that reactivation of autoreactive effector T cells in
their target organ is suppressed by BZ194 treatment, TMBP-GFP cells
were loaded on spinal cord explants from early EAE lesions and
their activation state tested 24h later by measuring pro-inﬂamma-
tory cytokine production. In the presence of BZ194, the TMBP-GFP
cells produced signiﬁcantly lower levels of IFN and interleukin-17
(Fig. 4G).
Interestingly, TMBP-GFP cells re-isolated from BZ194-treated ani-
mals fully retained their ability to respond to antigenic challenge
Figure 1 Continued
antagonism does not prevent primary immune responses. (C) Generation of TMBP cells is not compromised by BZ194. Lymph node cells of
BZ194-treated (black) or vehicle-treated (white) animals were isolated from draining lymph nodes 7 days p.i. with MBP, and their
proliferative response to speciﬁc antigen tested by adding MBP (left bars) or OVA (right bars). Cell proliferation was evaluated 72h later
by (
3H)dT incorporation. Proliferation is indicated as the ratio between stimulated and non-stimulated cells. Data represent mean
values SD of triplicate measurements. Representative data of ﬁve independent experiments including at least three animals per group.
(D) MBP-speciﬁc antibody production remains unchanged after BZ194 treatment. Levels of anti-MBP antibodies within the serum of
BZ194-treated (black) and vehicle-treated (white) animals were measured 0, 7 and 14 days p.i. with MBP. Data represent mean
values SD of triplicate measurements. Representative data of two independent experiments including three animals per group. (E) BZ194
does not change the pro-inﬂammatory cytokine proﬁle of TMBP cells in draining lymph nodes Day 5p.i. with MBP. Cytokine levels were
determined by quantitative polymerase chain reaction in the cultured lymph node cells of BZ194-treated (black) and vehicle-treated
(white) animals 48h after addition of MBP or OVA. Representative data of three independent experiments. Ig=immunoglobulin;
OD=optical density.
Table 1 Treatment of active and adoptive transfer EAE with BZ194
Treatment Number
of analysed
animals
Disease
onset (days
p.i.: active
EAE; h
p.t.: adoptive
transfer EAE)
Disease
duration
(days: active EAE,
hours: adoptive
transfer EAE)
Max. mean
clinical score
Clinical
disease
index
Max.
body
weight
loss (%)
a
Incidence
(%)
Mortality
(%)
Active EAE Treatment Days 0–14
BZ194 17 11 0* 4.7 0.6* 1.8 0.1* 4.4 3.7* 21 11* 77 0
Nicotinic acid 5 10 06  0 3.9 0.8 11.8 3.6 47 6 100 40
Vehicle 16 10 06  0 3.4 0.4 11.9 32 9  0 100 33
Active EAE Treatment Days 8–14
BZ194 5 11* 5* 1.7* 4.8 2.6* 20* 80 0
Vehicle 5 10 6 3.3 11.4 0.5 32 100 0
Adoptive transfer
EAE preventive
Treatment Days 0–4
BZ194 22 84 14* 138 7* 1.6 0.3* 5.1 3.6* 12 5* 82 0
Nicotinic acid 10 64 22 168 0 3.1 0.1 12.6 6.1 18 1 100 0
Vehicle 22 67 13 161 11 3.2 0.2 11.3 7.2 17 4 100 0
Untreated 8 67 17 165 5 3.0 0.5 12.5 6.1 20 3 100 0
Adoptive transfer
EAE therapeutic
Treatment Days 3–5
BZ194 8 75 24 3  16* 1.9 0.4 5 1.5* 13 3 100 0
Vehicle 8 72 06 0  16 2.1 0.2 7.5 1.6 13 5 100 0
Preventive treatment of active EAE (Days 0–14 post injection): three independent experiments with BZ194 or vehicle treatment, one experiment with nicotinic acid.
Treatment of active EAE during the effector phase (Days 8–14): one experiment with BZ194 and one experiment with vehicle. Adoptive transfer EAE (preventive treatment:
Days 0–4): ﬁve independent experiments for BZ194 or vehicle treatment and three experiments with nicotinic acid application or untreated controls; two experiments with
BZ194 or vehicle treatment for the therapeutic protocol (Days 3–5). Clinical disease index: cumulative clinical score over the entire disease course/rat.
a Maximal body weight loss: maximal body weight loss compared to the time of injection.
*P-value at least50.05.
NAADP interference in T cell-mediated autoimmunity Brain 2010: 133; 1930–1943 | 1935Figure 2 NAADP signalling is essential for efﬁcient activation of (auto)antigen-speciﬁc T cells. (A) Anti-proliferative effect of BZ194 in
CD4
+ effector T cells. Rat TMBP cells co-cultured with MBP-pulsed antigen presenting cells (APCs; shaded) or control antigen (OVA) pulsed
antigen presenting cells (unshaded) were incubated with increasing amounts of BZ194 (squares) or nicotinic acid (circles). Cell numbers
were quantiﬁed by cytoﬂuorometry 2 days later. Mean values SD of triplicate measurements. Representative data of 12 independent
experiments. *P 0.0001. (B)T MBP cells previously stimulated in the presence of BZ194 for 2 days were re-exposed to MBP- or
OVA-pulsed antigen presenting cells in the absence of BZ194. TMBP cells reactivity was determined by (
3H)dT incorporation 2 days later.
Proliferation is indicated as percent of control stimulated with MBP (resting TMBP cells, MBP stimulation: 3256 345 cpm; OVA
stimulation: 76 11cpm). Mean values SD of triplicate measurements. Representative data of three independent experiments. (C) and
(D) BZ194 is not toxic for T cells. (C)T MBP cells were stimulated for 2 days with MBP-pulsed professional antigen presenting cells.
Thereafter, the T cell blasts were incubated with the indicated amounts of BZ194. TMBP cells were quantiﬁed 24 (grey circles) and 96 (black
triangles) hours later by cytoﬂuorometry. (D) After the 96h-treatment with BZ194, the antagonist was washed out and the resting TMBP
cells were stimulated with speciﬁc (MBP, black) or control (OVA, white) antigen-pulsed antigen presenting cells. TMBP cells reactivity was
determined by (
3H)dT incorporation 3 days later. Values represent mean values SD of triplicate measurements. Representative data of
three independent experiments. t.p.=time point.
1936 | Brain 2010: 133; 1930–1943 C. Cordiglieri et al.when cultured in the absence of the antagonist (Supplementary
Fig. 9). These data conﬁrm the previous observation that BZ194
interferes with re-activation of the effector T cells by rendering the
cells reversibly non-responsive (Fig. 2B; Supplementary Fig. 4E).
Intravital imaging of BZ194-treated
effector TMBP-GFP cells
Using intravital two-photon laser scanning microscopy, we studied
the effector T cell behaviour in situ (Kawakami et al., 2005a;
Odoardi et al., 2007a; Bartholoma ¨us et al., 2009). We recently
detected that TMBP-GFP cells in the EAE lesions displayed character-
istic locomotion patterns: 35% of the inﬁltrated TMBP-GFP cells
were stationary in the target tissue, i.e. they were ﬁxed to
anchor points reminiscent of cells in the process of antigen recog-
nition; the other portion of cells (65%) was motile and moved
with high velocity through the compact CNS tissue (Fig. 5A–D)
(Kawakami et al., 2005a). In BZ194-treated animals, we observed
similar locomotion patterns; however, a higher fraction (480%) of
the effector T cells were motile in the meninges and the adjacent
dorsal spinal cord parenchyma, whereas only520% were station-
ary (Fig. 5A–D; Supplementary Videos 1 and 2). Furthermore, the
average velocity of the effector T cells within the EAE lesions was
increased (Fig. 5E). An analysis of individual cell trajectories,
instantaneous velocities and meandering indices (a measure of
the straightness of T cell movement) revealed that this increased
velocity after BZ194 treatment was not due to altered locomotion
characteristics of motile effector T cells, but rather because the
number of arresting T cells was decreased compared to controls
(Fig. 5). These data were conﬁrmed in acute spinal cord explants,
which allowed imaging throughout the cross-section of the spinal
cord (Fig. 5; Supplementary Videos 3 and 4).
Discussion
Autoimmune diseases are evoked by T cells reactive against spe-
ciﬁc autoantigens, which are presented in the attacked organs.
The acute phase of any autoimmune disease is initiated when
autoaggressive effector T cells invade their target organs and
become locally reactivated upon encountering the speciﬁc antigen.
The ensuing release of pro-inﬂammatory mediators sets the stage
for recruitment of further immune cells and the onset of clinical Figure 3 Effector T cells are more sensitive to NAADP
antagonism than naı ¨ve and long lived memory T cells.
(A) NAADP antagonism preferentially suppresses activation of
antigen-experienced effector T cells. OX 22
high (OX 22
+) naı ¨ve
T cells (black) or effector T cells (TMBP cells, grey and TOVA cells,
white) were activated with anti-CD3/CD28 antibody in the
presence of the indicated amounts of BZ194. (A) The
proliferative response was determined 2 days later by (
3H)dT
incorporation. For better comparability, proliferation is indicated
as a percentage of non-treated naı ¨ve (4658 249 cpm) and
effector T cells (TMBP 7391 232 cpm, TOVA 6490 272 cpm),
respectively. Data represent mean values SD of triplicate
measurements. Representative data of three independent
experiments. *P 0.01. (B) Memory T cells are less susceptible
to NAADP antagonism than effector T cells. Shown are the
effects of increasing amounts of BZ194 on antigen-speciﬁc
proliferation of TOVA-GFP memory (black) or TOVA-GFP effector
(white) cells. Quantiﬁcation of cell numbers was performed by
cytoﬂuorometry 2 days later. Proliferation is indicated as percent
of control (no BZ194 treatment). Data represent means SD of
three measurements from two independent experiments.
*P 0.05. (C) Cytoﬂuorometrical quantiﬁcation of ryanodine
receptor 1–3 in naı ¨ve T cells (shaded histograms, left panel) and
memory T cells (shaded histograms, right panel) compared to
effector TMBP cells (open overlay histograms). Representative
data of at least three independent experiments. RyR=ryanodine
receptor; Ig=immunoglobulin.
NAADP interference in T cell-mediated autoimmunity Brain 2010: 133; 1930–1943 | 1937Figure 4 NAADP-antagonist interferes with TMBP-GFP cell activation within the CNS. (A and B) Treatment of adoptive transfer EAE.
Clinical course (left) and disease incidence (right; Kaplan–Meier curve) of EAE after transfer of TMBP-GFP cells. Treatment performed with
preventive schedule (A; n=22 animals/group) and during effector phase (B; n=8 animals/group) with BZ194 (black) or vehicle (DMSO,
white). Grey bar: period of treatment: 0–96h post transfer (p.t.) (A); 72–120h p.t. (B). Cumulative data of ﬁve (A) and three (B)
independent experiments are shown (mean values SD). P-values measured by Mann–Whitney rank statistical test: *P 0.01,
**P 0.001, ***P 0.0001. (C) BZ194 reduces homing of encephalitogenic effector T cells into their target organ. Cytoﬂuorometric
quantiﬁcation of TMBP-GFP cells in the spinal cord (CNS) or the spleen of BZ194-treated (black) or vehicle-treated (white) animals 3 days
(upper panel) and 4 days (lower panel) p.t. Values represent mean values SD of triplicate measurements. Representative data of ﬁve
Continued
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et al., 2007a; Bartholoma ¨us et al., 2009).
Here, we tested a novel strategy to interfere with the activation
of autoaggressive effector T cells. To this end, we used BZ194, a
recently developed antagonist, which speciﬁcally interferes with
NAADP-mediated Ca
2+ signalling in T cells (Langhorst et al.,
2004; Dammermann, et al., 2009). The NAADP antagonist was
applied in EAE of the Lewis rat, a model for multiple sclerosis. First
preliminary results indicate that BZ194 is similarly effective in
experimental autoimmune neuritis of the Lewis rat, a model for
Guillain-Barre ´ syndrome (Hartung et al., 1988) that is induced by
transfer of P2-reactive effector T cells (data not shown). The EAE
and experimental autoimmune neuritis models are particularly well
suited to test T cell-directed therapies, since their pathologies are
strictly dependent on autoaggressive T cells. Furthermore, their
unrivalled reproducibility together with the possibility to use
genetically labelled autoaggressive effector T cells allowed us to
track as well as to characterize functionally the disease-inducing
cell populations throughout the disease course (Flu ¨gel et al., 1999;
Kawakami et al., 2004, 2005a; Odoardi et al., 2007b).
BZ194 treatment signiﬁcantly ameliorated clinical symptoms and
autoimmune inﬂammation in EAE. Autoreactive effector T cells
within CNS lesions showed reduced activatory levels upon treat-
ment with BZ194 and their numbers within the target organ were
reduced. Instead, the T cells accumulated within secondary lymph
organs and the blood (Fig. 4C; Supplementary Fig. 7A).
Autoaggressive TMBP-GFP cells during preclinical EAE were found
to migrate ﬁrst to lymph nodes and then to the spleen, before
they reached, via the blood, their target organ, where they were
stimulated to produce pro-inﬂammatory cytokines (Flu ¨gel et al.,
2001; Kawakami et al., 2004; Odoardi et al., 2007b). Brain anti-
gen-ignorant T cells (TOVA cells), in contrast, did not sponta-
neously invade the brain tissue, but rather re-circulated within
the blood and secondary lymphatic tissues (Flu ¨gel et al., 2001).
Thus, the migratory behaviour of the TMBP cells after BZ194 treat-
ment resembled the behaviour of brain antigen-ignorant T cells.
These observations and the ﬁndings that BZ194-treated effector T
cells readily respond to chemokine stimuli argue for the case that
BZ194 does not directly interfere with the migratory capacity of
effector T cells in peripheral lymphoid organs.
During EAE, the autoaggressive effector T cells enter their target
organ from leptomeningeal vessels where they come into contact
with menigeal/perivascular macrophages capable of presenting
myelin antigens (Bartholoma ¨us et al., 2009; Kivisa ¨kk et al.,
2009). These encounters and the ensuing reactivation of the effec-
tor T cells were found to be essential for their penetration into the
CNS parenchyma (Bartholoma ¨us et al., 2009). Notably, TMBP-GFP
cells, which arrived at their target organ during BZ194 treatment,
did not distribute evenly throughout the CNS parenchyma but
were rather preferentially located in leptomeningeal and perivas-
cular areas (Supplementary Fig. 7C). A similar cell distribution was
found in EAE lesions of animals in which local antigen presentation
was prevented by elimination of resident antigen presenting cells
via application of clodronate containing liposomes (Tran et al.,
1998).
Contacts between autoreactive effector T cells and resident anti-
gen presenting cells in the CNS were changed after BZ194 treat-
ment (Fig. 5). The percentage of T cells continuously strolling
through the CNS tissue was substantially increased, whereas the
amount of T cells with restricted motility that has been shown to
be in contact with antigen presenting cells (Kawakami et al.,
2005a; Bartholoma ¨us et al., 2009) was decreased. Recent live
imaging studies indicate that T cell contacts to antigen presenting
cells are regulated by Ca
2+ ﬂuxes resulting from antigen encoun-
ters. Thus, the arrest of thymocytes during positive selection and
deceleration of naı ¨ve T cells in contact with antigen loaded den-
dritic cells was found to be dependent on intracellular Ca
2+ eleva-
tion (Bhakta et al., 2005; Skokos et al., 2007).
Figure 4 Continued
independent experiments. P-values: *P 0.05, **P 0.01, ***P 0.005. (D) NAADP signalling is essential for efﬁcient re-activation of
effector TMBP-GFP cells within their target organ. Reduced expression of pro-inﬂammatory mediators in autoaggressive TMBP-GFP cells
within the CNS after BZ194 treatment. Quantitative PCR of TMBP-GFP cells sorted from spinal cords 3 and 4 days p.t. Black bars:
BZ194-treated; white bars: vehicle-treated animals. Values are normalized to b-actin mRNA. Representative data of three independent
experiments. All differences are statistically signiﬁcant (P-value at least  0.05) unless otherwise speciﬁed. ns, not signiﬁcant. (E and F)
BZ194 treatment does not interfere with migration capacity of ex vivo, in vitro or in vivo effector T cells. (E)T MBP-GFP cells were isolated ex
vivo from spleens (upper plots) of animals treated with BZ194 (0.5mM) (black bars) or vehicle (white bars) at Day 3 p.t., or cultured
(lower plots) for 3 days in presence of the inhibitor (black bars) or vehicle (white bars). Percentage of transmigration without or in presence
of the indicated chemokines was assessed by cytoﬂuorometry 6h after plating. (F) Three days after transfer of 2.5 10
6 effector TOVA-GFP
cells, animals were intrathecally (i.t.) injected with 150ng of lipopolysaccharide (LPS) (white bars) or equal volume of phosphate buffered
saline (PBS) (grey bars); 24h later, the numbers of GFP positive cells were determined in the spleen (left plot), blood and spinal cord (CNS;
middle plot) by ﬂow cytometry. Right plot: adoptive transfer of effector TOVA-GFP cells was performed as above. The animals received a
daily i.p. injection of BZ194 or vehicle from Days 0 to 3p.t. At the Day 3p.t. BZ194-treated (black bars) and vehicle-treated (white bars)
animals were i.t. injected with lipopolysaccharide; for control, vehicle-treated animals were also i.t. injected with phosphate buffered saline
(grey bars). The graph shows ratios of total number of GFP-positive cells detected in the spinal cord (CNS) relative to the numbers in the
blood (left) or in the spleen (right) on Day 4p.t. *P50.05; n.s.=not signiﬁcant. (G) BZ194 treatment reduces the activation of effector
T cells on CNS explants. TMBP-GFP cells were cultured for 2h in presence of BZ194 (black bars, pre-loading) or vehicle (white bars,
pre-loading) and then loaded on spinal cord explants from mild EAE animals (after loading) in presence of the antagonist (0.5mM; black
bars) or of the vehicle (white bars). Twenty-four hours later, T MBP-GFP cells were sorted out and the levels of IFN (left graph) and
interleukin-17 (right graph) were measured by quantitative polymerase chain reaction. Representative data of three independent
experiments are shown. Values normalized to b-actin mRNA. *P50.05. Right dot plots: corresponding protein expression of IFN-,
evaluated by ﬂow cytometry of TMBP-GFP cells isolated from spinal cord explants 36h after loading.
NAADP interference in T cell-mediated autoimmunity Brain 2010: 133; 1930–1943 | 1939Figure 5 BZ194 increases effector T cell motility within EAE lesions. The locomotion patterns of TMBP-GFP cells in EAE lesions at Day 4p.t.
were analysed in real time within the spinal cord using intravital two-photon laser scanning microscopy (A, C and E), or within spinal cord
explants using two-photon laser scanning microscopy or video ﬂuorescence microscopy (B, D and F). (A and B, left panels) The trajectories
of representative stationary (orange) and motile (yellow) TMBP-GFP cells in BZ194-treated (upper panels) or vehicle-treated (lower panels)
animals are shown: (A) intravital imaging; (B) spinal cord explant analyses (B); motile cells: displacements410mm/10min; stationary cells:
displacements510mm/10min. Magniﬁcation bar=10mm. (A and B, right panels) Superimposed trajectories are shown. Each coloured
line represents one cell. (A) Intravital analyses: two representative two-photon laser scanning microscopy movies comprising
88 (BZ194-treatment) and 85 (vehicle-treatment) TMBP-GFP cells are shown. (B) Spinal cord explants: two representative video microscopy
Continued
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onism acts on additional cell populations or T cell functions,
e.g. their interaction with other cells or with the extracellular
matrix. First experiments involving neuronal cells (Supplementary
Fig. 10) and glial cell cultures (Cordiglieri et al., results not pub-
lished) did not reveal any clear effects of BZ194 treatment on
functional or structural properties of neural cells. The function of
antigen presenting cells seems evenly unchanged upon BZ194
treatment (Supplementary Figs 2 and 5). Therefore, our data
strongly suggest that the clinical effects of BZ194 are due to
inefﬁcient re-activation of the autoaggressive effector T cells
within their target organ.
Previous studies indicated a complex T cell receptor-triggered
Ca
2+ signalling network regulated by tightly controlled metabo-
lisms and synergisms of NAADP (Gasser et al., 2006), IP3 (Guse
et al., 1995) and cyclic ADP-ribose (Guse et al., 1999). Thereby it
was suggested that NAADP, which peaks within seconds after T
cell receptor activation, acts as the initializing trigger supporting
later Ca
2+ release events by amplifying IP3- and cyclic ADP-ribose-
induced Ca
2+ release (Gasser et al., 2006). IP3 appeared within a
few minutes (Guse et al., 1995) followed by cyclic ADP-ribose
within tens of minutes, respectively (Guse et al., 1999). Why do
T cells need such a complex signalling network to ﬁne tune Ca
2+
responses? The decision of whether to continue or to stop Ca
2+
signalling may ultimately result in cell proliferation and exertion of
effector functions, or it may drive the T cell into a state of unre-
sponsiveness or cell death. The NAADP/Ca
2+ signalling pathway
seems to control this decision, since expression of the major cyto-
kine involved in T cell proliferation, interleukin-2, depends on a
full, NAADP-initiated Ca
2+ response. If the NAADP pathway is
blocked, Ca
2+ signalling is only partially activated. Therefore, it
does not provide a sufﬁciently long-lasting increase in the free
cytosolic Ca
2+ to allow Ca
2+/calmodulin- and calcineurin-depen-
dent translocation of nuclear factor of activated T cells (NFAT) into
the nucleus (Timmerman et al., 1996; Dammermann et al., 2009).
Expression of the pro-inﬂammatory cytokines IFN- and interleu-
kin-17 was evenly suppressed by BZ194 indicating that Ca
2+ sig-
nalling initiated by NAADP is also involved in these signalling
cascades.
Notably, BZ194 did not exert toxic effects. Effector T cells re-
isolated from BZ194-treated animals readily reacted towards expo-
sure to speciﬁc antigen after wash-out of the antagonist.
Obviously, this wash-out of BZ194, when analysed in cultured
or ex vivo-isolated effector T cells was very rapid, which explains
the immediate reactivity of the effector T cells after withdrawal
of the antagonist (Supplementary Fig. 11). Thus, blocking
NAADP-mediated Ca
2+ signalling by BZ194 at the very early
state of T cell activation seems to induce a state of transient
non-responsiveness in the effector T cells. The observed strong
elevations of the transcription factors egr-2 and -3, which have
been recently identiﬁed as potent regulators of T cell anergy
(Safford et al., 2005), point in this direction.
Ryanodine receptor 1 was recently identiﬁed as the putative
receptor for NAADP in effector T cells (Dammermann et al.,
2009). Our data indicate that T cells regulate this receptor accord-
ing to their functional state, which could explain the different
susceptibility to BZ194 inhibition. We found higher expression
levels in effector T cells compared to naı ¨ve and long-lived
memory T cells (Fig. 3C). Correlating with their low ryanodine
receptor 1 levels, naı ¨ve T cells in vitro were suppressed only
at BZ194-concentrations of 4750mM (Fig. 3A; Supplementary
Fig. 6B). Similar observations were made with long-lived
memory T cells (Fig. 3B; Supplementary Fig. 6B). At the concen-
trations observed in vivo ( 300mM, Supplementary Fig. 12)
primary immune responses, i.e. the generation of speciﬁc effector
T and B cells, were unhindered (Fig. 1C–E). This is of therapeutic
relevance, since the antagonist seemed to interfere selectively with
the function of antigen-primed effector T cells that are inhibited at
more than 10-fold lower levels of BZ194.
Current T cell-directed therapies in autoimmune disorders based
on synthetic peptides or altered peptide ligands aim to modulate
T cellular functions and to convert a pro-inﬂammatory TH1
response into an anti-inﬂammatory TH2o rT H3 driven immunity
(Aharoni et al., 1997; Weiner, 2004; Fontoura et al., 2005).
Alternative strategies interfere with antigen presentation to
T cells or T cell migration into their target organ (Miller et al.,
2003; Kappos et al., 2006; Markowitz, 2007). However, all
endeavours have been either insufﬁcient in dampening down the
Figure 5 Continued
recordings including 52 (BZ194) and 50 (vehicle) TMBP-GFP cells are shown. (C and D) Characterization of motile and stationary cells.
(C and D, left panels) Quantiﬁcations of motile and stationary TMBP-GFP cells in BZ194-treated (black) versus vehicle-treated (white)
animals. Data from intravital analyses represent mean values SD of three independent movies including 255 cells and 16 065 time
intervals per treatment (C); explant video microscopy data represent mean values SD of ﬁve independent movies including 304 cells and
31920 time intervals per treatment (D). *P 0.05. (C and D, right panels) The graphs show the meandering indices of TMBP-GFP cells of
BZ194-treated or vehicle-treated animals. The meandering index is calculated as total cell displacement divided by the path length of a cell
track. Intravital analyses: 340 cells in BZ194- and 223 cells in vehicle-treated animals were analysed. Values represent means SD from
three independent movies/treatment. Spinal cord explant analyses: 154 cells in BZ194-treated and 228 cells in vehicle-treated animals
were analysed. Mean values SD from ﬁve independent movies/treatments, including three video-microscopy movies and two two-
photon laser scanning microscopy recordings are shown. (E and F) Instantaneous velocities of TMBP-GFP cells in the EAE lesions. (E) Intravital
imaging: velocities of TMBP-GFP cells in BZ194-treated (black bars; total 340 cells; 8160 time points) or vehicle-treated (white bars; total 223
cells; 5352 time points) animals are shown. Data represent means SD from three independent movies/treatment. (F) Instantaneous
velocities of TMBP-GFP cells in spinal cord explants of BZ194-treated (black bars; total 154 cells; 3696 time points) or vehicle-treated (white
bars; total 228 cells; 5472 time points) animals. Mean values SD from ﬁve independent movies/treatment including three video
microscopy movies and two two-photon laser scanning microscopy recordings are depicted. Average velocities (VAV) are indicated.
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moting the risk of infectious complications, i.e. progressive multi-
focal leucoencephalopathy after application of anti-Very Late
antigen-4 (a4b1 integrin) (VLA4) antibody (Langer-Gould and
Steinman, 2006). Interfering with Ca
2+ signalling as an early and
essential component of T cell activation might represent an alter-
native and promising therapeutic approach, as is also indicated by
recent studies using speciﬁc inhibitors of the potassium channels
Kv1.3 or TWIK-related acid-sensitive potassium channel 1 (TASK1)
(Beeton et al., 2001, 2006; Bittner et al., 2009). These inhibitors
indirectly affect Ca
2+ signalling by modulating the long-lasting
plateau phase (Beeton et al., 2001). NAADP as a direct participant
in the Ca
2+ signalling machinery might serve as a novel potential
therapeutic target. NAADP antagonists interfered preferentially
with the function of antigen-experienced effector T cells. Of
note is that this also included human autoantigen-speciﬁc
T cells. Furthermore, BZ194 ameliorated autoimmune diseases
not only when given before the onset of the symptoms, but
also afterwards, even though the observed therapeutic effects
were less pronounced, most likely due to the fact that the CNS
invasion of the myelin-reactive effector T cells and their local re-
activation already starts during the preclinical phase of EAE
(Bartholoma ¨us et al., 2009). These observed features of BZ194
may ultimately be beneﬁcial for the treatment of human patients
with autoimmune diseases, and point to the necessity of exploring
this novel therapeutic approach in future.
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